New vaccine shows promise in rare eye cancer trial
Disease control
Completed
This early-phase trial tested a personalized vaccine made from a patient's own immune cells and tumor material for metastatic uveal melanoma, a rare eye cancer. Seventeen adults received the vaccine alongside standard treatments like immunotherapy or chemotherapy. The main goals …
Phase: PHASE1 • Sponsor: Hasumi International Research Foundation • Aim: Disease control
Last updated May 08, 2026 12:03 UTC